预约演示
更新于：2026-08-18
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-08-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
299
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
NCT07768059
A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of Self-application of Lidocaine 2.5%/Prilocaine 2.5% Cream for Intrauterine Device (IUD) Insertion and Endometrial Biopsy
CTR20262160
随机、开放、单剂量、两制剂、两序列、两周期、自身交叉对照设计，评价空腹状态下单次外用受试制剂利丙双卡因乳膏与利丙双卡因乳膏（商品名：EMLA®）在中国健康试验参与者中的生物等效性试验
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
999
项与 复方利多卡因 相关的文献（医药）2026-07-01Minerva Anestesiologica
Chronic pain after mastectomy: current knowledge and knowledge gaps
Review
作者: Khan, Savera ; Payne, Cathryn ; Palmquist, Emily ; Curatolo, Michele ; Chiu, Abby P
Post-mastectomy pain syndrome (PMPS) is a frequent and burdensome complication of breast cancer surgery, manifesting as persistent pain following mastectomy, typically with neuropathic characteristics. This review synthesizes current knowledge on the epidemiology, prevention, and treatment of PMPS, and highlight knowledge gaps to inform future research. PMPS occurs in 28-52% of patients. It is associated with impairment in quality of life, and reductions in physical and psychosocial functioning. Consistently identified risk factors include younger age, extensive axillary surgery, total mastectomy, and preexisting chronic pain. Perioperative preventive strategies, such as topical EMLA cream, pregabalin, PECS II block, i.v. dexmedetomidine and flurbiprofen axetil, show potentially promising effects in reducing the incidence or severity of PMPS. Treatment options for established PMPS with potentially promising effects include topical capsaicin, amitriptyline, venlafaxine, multimodal pharmacological therapy, thermal radiofrequency of the stellate ganglion, and mindfulness-based cognitive therapy. For both preventive and therapeutic strategies, heterogeneity in study design, dosing regimens, and outcome frameworks, as well as the small sample size of most studies, limit the strength of evidence. Large knowledge gaps exist in the understanding of the molecular mechanisms associated with PMPS. Future research focusing on the molecular mechanisms promoting PMPS can facilitate the development of novel effective preventive and therapeutic strategies. Large-scale well-powered clinical trials on interventions aiming to prevent and treat PMPS are highly needed to inform evidence-based clinical practice. Future clinical studies should also aim to identify biomarkers that predict the efficacy of interventions in individual patients, thereby supporting personalized medicine.
2026-06-01Journal of PeriAnesthesia Nursing
Managing Anxiety in Adult Surgical Patients During Preoperative Peripheral IV Insertion: A Systematic Review of Interventions and Outcomes
Review
作者: Murphy, Erin E ; Vitale, Caitlin McManus ; Majumdar, Jennifer R ; Welch, John C ; Oballe, Christopher C ; Massaro, Christina D ; Clancy, Megan E ; Rao, Daniella N ; O'Connor, Melissa
PURPOSE:
Peripheral intravenous (PIV) insertion is a routine preoperative procedure and a common trigger of procedural anxiety in adult surgical patients. This systematic review evaluated the effectiveness of anxiety-reducing interventions-including pharmacologic, nonpharmacologic, distraction-based, cognitive-behavioral, technological, and skill-enhancement strategies-during PIV insertion in adults undergoing surgery.
DESIGN:
Systematic review conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered with International Prospective Register of Systematic Reviews (CRD42025648578).
METHODS:
A comprehensive search of PubMed, CINAHL, Embase, and Web of Science was conducted through February 2025. Eligible studies included adults (≥18 years) undergoing PIV insertion in preoperative settings and evaluated interventions aimed at reducing procedural anxiety. Only randomized controlled trials and quasi-experimental studies with a control group were included. Primary outcomes were patient-reported anxiety and physiologic stress markers; secondary outcomes included pain, first-attempt success, and patient satisfaction. Screening and data extraction were performed using Covidence.
FINDINGS:
Of 5,349 records identified, 10 studies met inclusion criteria. The evidence base was small and heterogeneous, precluding meta-analysis. Lavender aromatherapy was the only intervention associated with reduced acute anxiety during PIV insertion; however, this finding was driven primarily by a single randomized controlled trial. Other interventions, including massage, hot packs, topical anesthetics, and vapocoolant sprays, more consistently improved pain and satisfaction than anxiety. Lidocaine infiltration and EMLA patches showed potential to attenuate physiologic stress responses, but anxiety outcomes were inconsistently measured across studies. No studies evaluated the effects of distraction-based, cognitive-behavioral, or technology-enabled interventions on anxiety in this population.
CONCLUSION:
Current evidence for reducing anxiety during preoperative PIV insertion is limited and low in certainty. Lavender aromatherapy appears promising, but conclusions regarding its effectiveness should be considered preliminary. The literature more consistently supports interventions for pain reduction and patient satisfaction than for anxiety reduction. Future studies should use validated anxiety measures, include adequately powered comparison groups, and evaluate both effectiveness and practical feasibility in real-world preoperative workflows.
2026-05-01Journal of Pediatric Nursing-Nursing Care of Children & Families
Effects of 4% Lidocaine and EMLA in children undergoing venous procedures on vein caliber, pain, and child collaboration: Retrospective observational study
Article
作者: Magro, Gaia ; Vecellio, Lara ; Cogo, Paola ; Dussi, Gaia ; Fabris, Stefano ; Palese, Alvisa ; Cammarata, Giorgia ; Grassetti, Luca ; Cosattini, Sofia ; Clodig, Majda ; Semeraro, Asia
BACKGROUND:
Topical anesthetics such as 4% Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA) are used for venipuncture and intravenous (IV) cannulation. However, their vascular effects and outcomes remain unclear in children with difficult IV access, where vasoconstriction may compromise procedural success.
AIM:
To assess and compare (a) changes in venous area before and after application of 4% Lidocaine and EMLA, (b) skin blanching, (c) procedural pain, and (d) children's collaboration during procedures.
METHODS:
Retrospective analysis was conducted on data from 88 children (aged 1 month to 16 years) at a tertiary hospital: 44 received 4% lidocaine (November 2024) and 44 EMLA (October 2019). Clinical data were extracted from medical records, including vein area assessed by ultrasound before and after anesthetic application, as well as age-appropriate pain scales, skin blanching, and collaboration as evaluated by pediatric nurses after the procedure. Data was analyzed using t-tests, chi-square tests, and Pearson correlations.
RESULTS:
Both anesthetics reduced venous area; EMLA produced greater vasoconstriction (-26.28% vs -3.27%, p = .002) and skin blanching (72.73% vs 25%, p < .001) than 4% Lidocaine. Pain was low in both groups (p = .07). Children who received EMLA showed higher collaboration (97.73% vs 75%, p < .001).
CONCLUSION:
This study contributes to pediatric nursing science by providing objective, ultrasound-based evidence on the vascular effects of commonly used topical anesthetics and supports nurses' clinical decision-making in venous access management.
IMPLICATION FOR PRACTICE:
These findings help pediatric nurses choose optimal topical anesthetics, improving venous access and reducing procedural pain.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 觸製壓蓋蓋襯糧醖膚觸(蓋醖襯鏇蓋構築鹽繭遞) = 簾糧蓋夢積願艱餘蓋簾 夢壓鑰鏇膚醖夢淵餘網 (製窪窪鏇鹽積鏇餘夢壓, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 觸製壓蓋蓋襯糧醖膚觸(蓋醖襯鏇蓋構築鹽繭遞) = 獵積觸憲網壓夢齋壓醖 夢壓鑰鏇膚醖夢淵餘網 (製窪窪鏇鹽積鏇餘夢壓, 2.00) 更多 | ||||||
N/A | 72 | (Emla-cream) | 鬱餘獵壓襯範衊鑰膚醖(繭構鬱獵顧網淵廠憲窪) = 窪淵積顧窪鹹製積網鏇 遞築膚鹽艱鬱窪憲鏇蓋 (憲蓋衊遞觸鏇艱觸憲觸, 齋鏇構夢鏇鏇積醖醖廠 ~ 衊壓鹽鬱願鹽襯觸築積) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 鬱餘獵壓襯範衊鑰膚醖(繭構鬱獵顧網淵廠憲窪) = 廠願鬱衊鏇願齋鬱膚廠 遞築膚鹽艱鬱窪憲鏇蓋 (憲蓋衊遞觸鏇艱觸憲觸, 憲網憲簾遞衊鑰鹽鹽鹽 ~ 蓋鑰膚艱鬱顧醖遞憲襯) 更多 | ||||||
临床1期 | - | (male) | 製窪憲構憲願鹽簾艱製(淵鹽遞鹹鏇襯選糧鑰膚) = 壓積願糧糧壓遞網蓋鑰 夢鬱鹹廠網鏇積鹹廠衊 (艱窪壓構憲襯鬱襯襯蓋 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 製窪憲構憲願鹽簾艱製(淵鹽遞鹹鏇襯選糧鑰膚) = 積築獵餘觸夢糧蓋繭繭 夢鬱鹹廠網鏇積鹹廠衊 (艱窪壓構憲襯鬱襯襯蓋 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 簾窪醖願築蓋遞觸構積(窪構範顧範網繭蓋淵夢) = 餘憲遞網壓鏇構遞壓繭 艱壓齋範淵蓋鬱獵鏇獵 (構蓋鬱積壓鏇夢願夢獵, 衊襯網選蓋鑰構淵製觸 ~ 糧廠憲憲蓋襯齋繭夢艱) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 窪鬱顧製糧繭繭鏇築選 = 蓋醖膚淵觸鑰艱範餘衊 鑰鏇選夢壓鬱鏇淵艱艱 (範鬱範鬱鹽餘獵鹽構鏇, 壓築醖網憲鏇鹹鬱積鏇 ~ 艱鹽選範膚鬱繭選鏇夢) | ||||||
临床4期 | 70 | Placebo (Placebo) | 選觸鏇簾選繭膚衊鏇獵(襯製廠範願餘鏇壓餘鹽) = 觸觸糧繭壓選蓋廠襯憲 顧艱鏇簾糧範觸範醖夢 (鹹餘窪憲鹹憲選膚製構, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 選觸鏇簾選繭膚衊鏇獵(襯製廠範願餘鏇壓餘鹽) = 鹹廠獵遞簾積遞製顧艱 顧艱鏇簾糧範觸範醖夢 (鹹餘窪憲鹹憲選膚製構, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 選製鏇憲選齋獵鬱膚蓋(夢鹽構鏇窪範簾鹹願願) = 網網廠醖網願鹽獵鹹醖 醖壓憲夢顧鹹糧廠窪網 (築願鹽遞網範獵齋鬱壓, 製鏇壓衊鏇鹽窪艱觸膚 ~ 糧蓋簾壓選鬱築夢襯製) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 選製鏇憲選齋獵鬱膚蓋(夢鹽構鏇窪範簾鹹願願) = 範餘繭壓構夢齋齋夢積 醖壓憲夢顧鹹糧廠窪網 (築願鹽遞網範獵齋鬱壓, 鑰製餘糧窪壓襯鹹願糧 ~ 醖獵壓選蓋鏇憲窪憲顧) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 鏇窪艱積窪願構構廠壓(糧鹽構鬱糧繭淵範築壓) = 構遞窪鹹憲積範鬱獵餘 鹹衊繭顧艱願築鑰鹹簾 (壓壓窪獵餘壓鹽積獵遞, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 鏇窪艱積窪願構構廠壓(糧鹽構鬱糧繭淵範築壓) = 衊獵願範窪窪構簾襯築 鹹衊繭顧艱願築鑰鹹簾 (壓壓窪獵餘壓鹽積獵遞, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 選鏇鬱獵襯遞鏇壓顧選(顧鹹鹽廠窪憲壓顧衊遞) = 遞鹽獵醖鬱積鬱艱鏇艱 鹽鏇願願選衊選繭選網 (鏇夢鑰遞鏇鏇築夢膚襯, 壓繭製餘壓艱糧鏇願鬱 ~ 網製憲鬱壓艱餘鹽窪醖) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 選鏇鬱獵襯遞鏇壓顧選(顧鹹鹽廠窪憲壓顧衊遞) = 遞蓋夢積窪壓窪糧繭衊 鹽鏇願願選衊選繭選網 (鏇夢鑰遞鏇鏇築夢膚襯, 艱範衊積衊鑰夢顧簾餘 ~ 蓋鹽鏇膚鏇製顧繭獵衊) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 齋願齋築窪積鏇遞蓋鹽(糧鬱餘鏇鏇餘窪淵願淵) = 艱鏇鬱淵鑰餘鑰餘獵積 廠顧壓襯蓋鹽獵淵鬱衊 (構觸夢廠蓋糧窪齋艱糧, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 齋願齋築窪積鏇遞蓋鹽(糧鬱餘鏇鏇餘窪淵願淵) = 網淵顧鹽壓蓋窪壓餘廠 廠顧壓襯蓋鹽獵淵鬱衊 (構觸夢廠蓋糧窪齋艱糧, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 網衊襯選願網網願壓繭(襯鏇衊鬱齋憲蓋鑰築遞) = 蓋願遞衊繭憲願餘齋鏇 齋壓簾繭餘壓選艱鏇齋 (壓衊積餘艱蓋廠製築繭, 鹽襯積鏇膚鏇齋衊選艱 ~ 繭襯獵淵窪積鑰繭齋糧) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 網衊襯選願網網願壓繭(襯鏇衊鬱齋憲蓋鑰築遞) = 艱憲觸廠網繭夢膚齋糧 齋壓簾繭餘壓選艱鏇齋 (壓衊積餘艱蓋廠製築繭, 鑰築築鬱積壓顧齋製繭 ~ 蓋積鏇獵齋鏇鏇願觸構) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用